SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+2.21%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$223M
AUM Growth
+$223M
(-23%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-18.79%
Top 10 Holdings %
Top 10 Hldgs %
38.27%
Holding
101
New
18
Increased
23
Reduced
24
Closed
32
Top Buys
| 1 |
Merus
MRUS
|
$7.25M |
| 2 |
89bio
ETNB
|
$6.67M |
| 3 |
Viking Therapeutics
VKTX
|
$6.33M |
| 4 |
Karyopharm Therapeutics
KPTI
|
$6M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$5.69M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$10.6M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$9.67M |
| 3 |
Immunovant
IMVT
|
$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$5.62M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$5.09M |
Sector Composition
| 1 | Healthcare | 95.65% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $12.3M | 5.08% | 668,784 +394,080 | +143% | +$7.25M |
|
2
MacroGenics
MGNX
$112M
| $9.76M | 4.03% | 1,361,809 +749,334 | +122% | +$5.37M |
|
|
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
| $9.67M | 3.99% | 2,793,748 +388,388 | +16% | +$1.34M |
|
|
PSTX
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $8.28M | 3.42% | 2,689,301 +459,301 | +21% | +$1.41M |
|
5
Oric Pharmaceuticals
ORIC
$994M
| $8.18M | 3.38% | 1,435,945 +199,649 | +16% | +$1.14M |
|
6
Terns Pharmaceuticals
TERN
$609M
| $7.91M | 3.26% | 667,922 -32,078 | -5% | -$380K |
|
7
Akero Therapeutics
AKRO
$3.74B
| $7.75M | 3.2% | 202,561 +30,461 | +18% | +$1.17M |
|
8
Nuvalent
NUVL
$5.52B
| $7.35M | 3.03% | 281,533 -21,430 | -7% | -$559K |
|
|
BLU
9
DELISTED
BELLUS Health Inc.
BLU
| $7.2M | 2.97% | 1,000,000 -707,370 | -41% | -$5.09M |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.77M | 2.79% | 125,035 -15,331 | -11% | -$830K |
|
|
11
89bio
ETNB
$1.34B
| $6.67M | 2.76% | +438,215 | New | +$6.67M |
|
|
12
Viking Therapeutics
VKTX
$3.04B
| $6.33M | 2.61% | +380,000 | New | +$6.33M |
|
13
Cogent Biosciences
COGT
$1.69B
| $6.25M | 2.58% | 579,264 +400,264 | +224% | +$4.32M |
|
|
14
Karyopharm Therapeutics
KPTI
$61.7M
| $6M | 2.48% | +1,541,426 | New | +$6M |
|
|
15
KalVista Pharmaceuticals
KALV
$678M
| $5.69M | 2.35% | +723,544 | New | +$5.69M |
|
16
Schrodinger
SDGR
$1.44B
| $5.6M | 2.31% | 212,825 +104,825 | +97% | +$2.76M |
|
17
Gilead Sciences
GILD
$140B
| $4.99M | 2.06% | 60,130 +8,168 | +16% | +$678K |
|
18
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.82M | 1.99% | 577,757 +305,584 | +112% | +$2.55M |
|
19
Veracyte
VCYT
$2.39B
| $4.68M | 1.93% | 209,653 +9,653 | +5% | +$215K |
|
20
Pharvaris
PHVS
$1.39B
| $4.51M | 1.86% | 559,387 +459,387 | +459% | +$3.7M |
|
21
United Therapeutics
UTHR
$13.8B
| $4.16M | 1.72% | 18,578 +2,530 | +16% | +$567K |
|
22
Vertex Pharmaceuticals
VRTX
$100B
| $4.15M | 1.71% | 13,181 +1,797 | +16% | +$566K |
|
23
Regeneron Pharmaceuticals
REGN
$61.5B
| $4.11M | 1.7% | +5,000 | New | +$4.11M |
|
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $3.46M | 1.43% | 96,643 -157,012 | -62% | -$5.62M |
|
25
Cerus
CERS
$251M
| $3.42M | 1.41% | 1,152,902 -481,112 | -29% | -$1.43M |
|